Related references
Note: Only part of the references are listed.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
COVID-19: combining antiviral and anti-inflammatory treatments
Justin Stebbing et al.
LANCET INFECTIOUS DISEASES (2020)
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission
Jennifer Lighter et al.
CLINICAL INFECTIOUS DISEASES (2020)
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
Xiaobo Yang et al.
Lancet Respiratory Medicine (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China
Giuseppe Lippi et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
F. La Rosee et al.
LEUKEMIA (2020)
Questioning the Effectiveness of Baricitinib for Pulmonary Manifestations of Rheumatoid Arthritis
Jason Chertoff et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
Share Paper
